Johnson & Johnson GENERAL — Sales to customers (Note 9) decreased by 1.0% to $2.76B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.0%, from $2.65B to $2.76B. Over 2 years (FY 2021 to FY 2024), GENERAL — Sales to customers (Note 9) shows an upward trend with a 10.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market demand or successful commercial execution within this specific business area, while a decrease may signal market saturation, competitive pressure, or product lifecycle maturity.
This metric represents the total revenue generated from the sale of products or services within the specific business se...
Comparable to segment-specific net revenue or product line sales reported by diversified healthcare or consumer goods conglomerates.
jnj_segment_general_sales_to_customers_note_9| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.51B | $2.71B | $2.52B | $2.70B | $2.58B | $2.59B | $2.53B | $2.63B | $2.63B | $2.66B | $2.69B | $2.65B | $2.71B | $2.65B | $2.78B | $2.76B |
| QoQ Change | — | +8.0% | -6.9% | +6.9% | -4.5% | +0.5% | -2.3% | +4.1% | -0.1% | +1.2% | +1.2% | -1.5% | +2.3% | -2.5% | +5.2% | -1.0% |
| YoY Change | — | — | — | — | +2.7% | -4.5% | +0.3% | +2.2% | +1.6% | — | +2.3% | +0.8% | — | -0.6% | +3.4% | +4.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.